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1. Introduction 
1.1 Liver and its physiology 
The liver, the largest organ in the body, predominantly functions as a biochemical 
laboratory where metabolism takes place. It has both endocrine and exocrine functions; and 
is also involved in numerous metabolic activities and acting as a storage depot. Once the 
nutritional substances and other chemicals such as drugs, carcinogens etc. reach in liver, 
they are metabolized by hepatic enzymes. The organ is located on the right side of the 
abdomen just beneath the diaphragm in human. Liver is a solid organ consisting of several 
lobes. Each lobe is constituted with numerous lobules which are in general hexagonal in 
shape (Figure 1). The center of each lobule is occupied by the central vein and the periphery 
of the lobule is delineated by a close arrangement of hepatic artery, portal vein, and bile 
duct; called “portal triads”. The portal triads appear at the vertices of the hexagonal lobules. 
The vessels generated from the portal triads ramify and distribute along the sides of the 
lobule, and open into the sinusoids which have thin epithelial lining, a discontinuous layer 
of fenestrated endothelial cells. The liver has different types of cells. Oval cells are generally 
found near the portal triad. This rare cell-type has been claimed as hepatic stem cells by 
some researchers (Zamule et al., 2011). However, the major cell-type in liver is the polygonal 
hepatic parenchymal cells (hepatocytes). Hepatic lobules are made up of more than 80% 
hepatocytes which have an average size of 25  and occupy 70-90% of liver mass, depending 
on the species. They have clear cell membrane; sometimes with two nuclei. They have large 
deposits of glycogen, often with lipid droplets and basophilic materials. They also contain 
other cellular organelles such as mitochondria, rough endoplasmic reticulum (granular) and 
smooth endoplasmic reticulum (agranular), golgi apparatus, and lysosomes. The 
hepatocytes are arranged in stacks of anastomosing plates, separated by an anastomosing 
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system of sinusoids. One or two cells thick hepatocytes appear radiating from central vein 
towards the periphery. They metabolize and excrete into sinusoids or bile canaliculi. They 
can undergo cell division to produce more hepatocytes. Other than the endothelial cells, the 
liver sinusoids contain phagocytic cells derived from monocytes, known as Kupffer cells. 
These macrophages phagocytize particulates and cell debris. Another hepatic cell-type is 
known as the ito cell. These are adipose or stellate cells.  
Liver undertakes several important functions in our body. It 
 produces bile which contains bile salts (sodium glycocholate, sodium taurocholate). The 
bile salts emulsify fats and oils and thus help in the digestion of them.  
 involves in carbohydrate and fat metabolism, hemoglobin metabolism and lipid 
synthesis. 
 stores many chemicals such as glycogens, vitamins, minerals and several metabolites. 
 involves in detoxification and removal of many toxic chemicals, including drugs, 
carcinogens, and various toxins through bile from the body. 
 converts circulating ammonia into urea by urea cycle (Ornithine cycle) and thereby 
reduces ammonia level in blood. 
 produces serum proteins such as albumin, clotting factors. 
1.2 Hepatic regenerative capability 
Under normal condition in an adult, liver maintains its size. However, liver has the 
regenerative capacity. Under various stress conditions, liver-size may increase. Numerical  
 
Fig. 1. Histological structure of a liver lobule 
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increase in hepatic cells by rapid cell division (hyperplasia) or increase in cell-size 
(hypertrophy) primarily causes enlargement of the tissue (Michalopoulos & DeFrances, 
1997). Exposure to high levels of chemical toxicants causes increase in liver-size about 2-3 
times of its normal size to combat the enhanced metabolic pressure exerted by chemical 
exposure (Michalopoulos & DeFrances, 1997).  By regeneration process liver replaces the 
necrotic/ dead cells or the cells damaged due to toxicity. During hepatic continual 
regeneration process, the increased collagen synthesis and deposition result in fibrosis. This 
alongwith further continual hepatic cell damage due to various stress conditions cause liver 
cirrhosis (Lv et al., 2006). In cirrhosis, liver morphology alters. Scarring and nodularity 
appear. Normal hepatic function suffers and hepatic homeostasis decreases.   
1.3 Liver cancer and its types  
Cancer is the uncontrolled proliferation of cells that is caused by the multi-genetic defects. 
When the phenomenon occurs in liver cells, this is called hepatic cancer or liver cancer. The 
cancerous process begins in a few cells and the cells become immortal. They invade adjacent 
cells, intrude other nearby tissues (sometimes tissues at a distance) and metastasize.  
Uncontrolled proliferation of the cells causes solid mass formation in liver, resulting hepatic 
tumor. The predominant risk factors and etiological agents responsible for hepatocellular 
carcinoma in humans have been identified as chronic infection with hepatitis B virus or 
hepatitis C virus, exposure to aflatoxin B1 or other chemical carcinogens, and alcoholic 
cirrhosis and cirrhosis associated with genetic liver diseases. 
1.3.1 Primary liver cancer 
Primary liver cancer means that the cancerous process occurs and develops primarily in 
liver and does not start from the spread of cancerous cells located outside the liver. It is the 
most common type of hepatic cancer. There may be several causes of primary liver cancer.  
Chronic viral infections such as hepatitis B or C, some toxins, chemical induced hepatic 
damage, radiation-induced hepatic damage, and chronic liver diseases such as cirrhosis can 
cause primary liver cancer. Primary liver cancer has different types, too. 
1.3.1.1 Hepatocellular carcinoma (also called hepatoma) 
Hepatocellular carcinoma is the incidence of primary liver cancer in liver parenchyma cells 
or hepatocytes. People suffering from liver chronic diseases such as cirrhosis of liver are 
more prone to hepatocellular carcinoma. This is common to adult patients. However, in 
children and teenagers, similar pattern of the disease is called hepatoblastoma.  
1.3.1.2 Cholangiocarcinoma 
When primary liver cancer occurs in bile ducts it is called cholangiocarcinoma. 
1.3.1.3 Angiosarcoma and hemangiosarcoma 
These are fast growing rare type liver cancers. 
1.3.1.4 Angiosarcoma 
This rare form of rapidly growing fatal tumor develops in the endothelial cells of blood 
vessel of the liver.  
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1.3.1.5 Hemangiosarcoma 
This is also developed from the lining of blood vessel, however, with relatively a slow 
speed. Blood-filled channels and spaces can be delineated under microscope. This is highly 
invasive type of cancer.  It is commonly found in children. In patients suffering from 
hemangiosarcoma, the rapture of tumor leads to bleeding to death. 
1.3.2 Secondary liver cancer 
Malignant cells migrated from any tissues other than liver may invade hepatic tissue and 
develop neoplastic tumor in liver. This is described as secondary liver cancer. Spread of 
cancerous cells from outside the liver to the liver through blood flow or through the 
lymphatic system, the anchorage of the cells in liver, angiogenesis (formation of new blood 
vessels for supply of food and oxygen for new cells), and cellular proliferation leading to 
solid growth of mass are the possible sequences of secondary liver cancer. It is also called as 
metastatic cancer.  
1.3.3 Experimental liver cancer in animals 
Cancer in general is a multistage complex process by which uncontrolled proliferation of 
cells occurs. To understand the underlying mechanism in the process of development of 
the disease and its progress, it is important to develop the strategy to combat the 
dreadful disease. The need for the development of various in vivo cancer models has 
been in demand. Experimental liver cancer in animals is thus developed for studying the 
progress of the disease scientifically minutely in vivo and to develop therapeutic and 
other combating strategies to fight against it. There are various in vivo animal models 
already available for the purpose. Generally, virus-induced, radiation-induced, 
neoplastic cell-transplanted and chemical-induced liver cancer animal models have been 
widely studied. 
2. Hepatocarcinogenesis 
Hepatocarcinogenesis is the development of liver cancer due to the exposure of carcinogen 
(a chemical that produces cancer). Many hepatocarcinogens such as aflatoxins, 
acetylaminofluorene, diethylnitrosamine have been successfully used to develop 
hepatocarcinogenesis in animals. Experimentally, hepatocarcinogenesis is developed using 
different carcinogens and also in different animal species. Several genetic and epigenetic 
changes such as chromosomal deletions, rearrangements, aneuploidy, gene amplification, 
and mutations, formation of DNA adducts, DNA strand-break, modulation of DNA 
methylation, and modulation of cell signaling pathways, due to direct or indirect effect of 
carcinogen exposure lead to neoplastic transformation of hepatocytes in experimental 
animals. Hepatocarcinogenesis is a multistage complex process, which is preceded by early 
appearance of morphologically and genetically altered hepatic focal lesions, also known as 
preneoplastic lesions. Initially monoclonal populations of hepatocytes evolve primarily due 
to carcinogenic insult. These aberrant monoclonal populations of regenerative hepatocytes 
(focal lesions) develop hyperplastic nodules to dysplastic nodules, leading to hepatocellular 
carcinoma. 
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3. Hepatocellular carcinoma 
The most common primary malignant tumor of liver is hepatocellular carcinoma. This 
primary liver cancer is also called hepatoma. As described above, liver has different types of 
cells such as hepatocytes, billiary cells, blood cells, Kupffer cells,  ito cells, perisinusoidal 
cells etc. However, about more than 80% of liver tissue consists of hepatocytes. The majority 
of primary liver cancer (>90%) arises from hepatocytes and is called hepatocellular 
carcinoma. During hepatocarcinogenesis, initial carcinogen insult results in initiated cells 
from normal liver parenchyma cells or hepatocytes by genetic alteration following an 
interaction generally with DNA. Subsequent tumor promotion by chronic exposure of 
carcinogen or a tumor promoter such as phenobarbital develop clonally selected expansions 
of initiated cell populations called  hepatic altered foci by fixing the mutations for further 
genetic changes. Additional accumulations of genetic changes within these foci produce 
hyperplastic nodules that ultimately lead to the development of hepatocellular carcinoma.  
3.1 Stages of hepatocellular carcinoma 
Transformation of the initiated hepatocytes into hepatocellular carcinoma is a multistage 
complex process. Based on the various morphological (such as appearance, size, shape, 
growth) and biochemical (such as variation in staining patterns, and altered enzyme 
expression patterns) changes of these hepatocytes, leading to hepatocellular carcinoma, 
various stages of development of the disease, namely initiation, promotion and progression, 
have been described to understand the progress of the disease in a more defined way and to 
develop better therapeutic strategies.  
3.1.1 Initiation 
Exposure of genotoxic agents such as aflatoxins, 2-acetylaminofluorene,  diethylnitrosamine, 
ionizing radiation etc. alters DNA sequence, causing mutations in the hepatocytes that  
 
Fig. 2. Glycogen-stored early preneoplastic focal lesion (shown by yellow arrows) in rat 
hepatic tissue with Periodic Acid Schiff reaction. (Mukherjee et al. 2005) 
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develop potential to begin the transformation of normal cells to cancer cells. The mutations 
generally activate proto-oncogenes and/or inactivate tumor suppressor genes to develop 
hepatocellular carcinoma in the carcinogenic mechanism. The chemicals that cause the 
process (initiation) are called “initiators”. Initiation is an irreversible process for a small 
population of cells. It occurs with a single/ brief exposure to a carcinogen. Electrophilic 
moieties generated by genotoxic agents generally bind with DNA to form DNA adduct, 
hamper cellular DNA repair mechanism, and develop permanent DNA lesions. Thus, the 
normal cell becomes an initiated cell. The initiated cells can develop focal lesions (Figure 2), 
one or more of which can act as sites of origin for the subsequent development of malignant 
neoplasia (Farber & Sarma 1987). 
3.1.2 Promotion  
Initiated hepatocytes are unable to grow autonomously (Farber & Sarma 1987), although 
they gain the potential to favor proliferation by possessing alterations in gene and protein 
expressions. Upon exposure to an environment where initiated cells are at greater risk, 
further genetic alterations begin, causing some reversible changes in the initiated cell 
populations. Repeated or long-term exposure to a promoting agent (phenobarbital, dietary 
fat, ethanol, estrogens, chronic exposure of carcinogens) or by some processes (e.g., partial 
hepatectomy), or by physiological condition (e.g., the neonatal liver) or diseased liver (virus 
infected or cirrhotic liver), the initiated cells induce focal proliferations. It begins with a 
selective, clonal amplification of the initiated cells into focal proliferations.  
3.1.3 Progression 
One or more focal lesions from the promotion phase further proceed for more genetic and 
enzymatic alterations in the constituted hepatocytes, forming enzyme-altered foci. Such a 
lesion may form from a single lesion or by merging several lesions and may be large enough 
to form a macroscopic structure (hepatic nodule) (Figure 3) in the liver. They sometimes  
 
Fig. 3. An external morphology of liver tumor of a carcinogen-control rat showing multiple 
grayish-white and greenish-white  hyperplastic nodules on the liver surface. (Das et al. 2010) 
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look grey or whitish gray or greenish (because of the presence of bile in them). Eventually by a 
slow process through lots of biochemical and genetic alterations those hepatic altered foci or 
hepatic nodules develop increasingly malignant cellular characteristics and are transformed 
into neoplasia without any further external stimulus or intervention (Farber & Sarma 1987). 
4. Sequential changes in hepatocellular lineages leading to hepatocellular 
carcinoma 
Etiology of hepatocellular carcinoma has probably been studied and analyzed in the best 
defined manner. Various groups of scientists have studied minutely and described the process 
of development of hepatocellular carcinoma during hepatocarcinogenesis. Other than 
initiation, promotion and progression models, Bannasch and his coworkers (Bannasch, 1995) 
have established and described the involvement of defined cellular lineages in the process of 
development of liver cancer. Predominant sequential cellular changes during the development 
of  hepatocellular carcinoma commence with glycogenotic clear and acidophilic (due to 
proliferation of smooth endoplasmic reticulum) cell focal lesions and progress through 
intermediate phenotype of mixed cell population to glycogen poor basophilic (ribosome rich) 
cell phenotypes (Figure 4). The group has described few other cellular lineages. In the tigroid 
basophilic lineage, initially the cells have abundant highly ordered stacks of the rough 
endoplasmic reticulum and thereby they have uniqueness. The scientist group further 
reported that the lineage is common to the animals treated with a low dose treatment of 
hepatocarcinogen (Gournay et al., 2002). Another type of cellular lineage has been found to 
involve in the development of hepatocellular carcinoma. Rats when treated with non-
genotoxic peroxisome proliferators or woodchucks chronically infected with woodchuck 
hepatitis virus showed foci with glycogen-poor cytoplasm containing abundantly granular 
acidophilic (mitochondria and peroxisome proliferators) and basophilic (ribosome) 
components (Bannasch et al., 1998). They named it amphiphilic cell lineage. 
 
Fig. 4. Mixed cell focal lesion (shown by green arrows) and basophilic lesion (shown by blue 
arrows) in diethylnitrosamine-treated rat liver. (Mukherjee et al. 2007) 
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5. Biochemical modulation in hepatocellular carcinoma 
As discussed above, from the beginning of initiation process to the development of 
neoplasm, various biochemical and genetic changes occur in the affected cells. Some of these 
changes are well-distinguishable and vary along with the stages of development during 
various cancer processes including hepatocarcinogenesis. They have been described as 
preneoplastic or neoplastic markers, depending on the developmental stages (Pérez-Carreón 
et al., 2006). Liver is the largest organ in our body and it takes major role in metabolism. It 
has several enzymes which take part in metabolism and detoxification of various chemicals, 
including drugs. Most of these enzymes were discovered during investigation of drug 
metabolism in liver and thus they are called hepatic drug metabolizing enzymes. In liver, 
glutathione and related enzymes such as glutathione peroxidase, glutathione reductase, 
superoxide dismutase, catalase and many other hepatic drug metabolizing enzymes and 
isoenzymes, such as glutathione-S-transferases (GSHT), UDP-glucuronyl transferases 
(UDPGT), cytochrome-c-reductase, cytochrome P-450 content and cytochrome b5, have been 
identified as possible markers of preneoplastic and neoplastic hepatocytes (Mukherjee et al., 
2005; Sarkar et al., 1994). They are categorized as Phase I and Phase II drug metabolizing 
enzymes/ isoenzymes. Variation in different such enzyme and isoenzyme levels, enzyme 
expression patterns assessed by histochemistry, lipid peroxidation profile, oxidative stress 
markers etc., during hepatocarcinogenesis, has been studied and reviewed by several 
workers (Sarkar et al., 1994,). Conjugation of toxic metabolites with cellular macromolecules 
such as proteins and nucleic acids, may lead to several health problems including cancer. 
The enzymes (glutathione S-transferases, arylhydrocarbon hydroxylases, UDP-glucuronic 
trasferases, cytochrome monooxygenases etc.) and isoenzymes (cytochrome b5, cytochrome 
C etc.) are mostly involved in the detoxification process in liver. In Phase I hepatic metabolic 
reaction, oxygenation and hydroxylation reactions and in Phase II metabolic reaction in 
liver, glucuronidation and transferase reactions are very predominant. Glucuronic acid is 
transferred from uridine diphosphate glucuronic acid to a drug or phase I metabolite by the 
enzyme UDPGT (Vessey, 1996). Thus inefficient phase II processes cause increased 
deposition of phase I toxic metabolites. Another very important class of transferase enzymes 
is GSHT. They take enormous role in phase II detoxification process in liver. They detoxify 
electrophilic groups and thus inactivate even the function of carcinogens or mutagens. Satoh 
and Hatayama (Satoh & Hatayama, 2002) reported that specific different forms of GSHT are 
expressed during initiation, promotion and neoplastic cell populations. In the different 
developmental stages of hepatocellular carcinoma, glutathione peroxidase  and reduced 
triphosphopyridine nucleotide (TPNH)-cytochrome-c-reductase  activities, cytochrome b5  
and P-450 contents, glutathione content  and superoxide dismutase and catalase activities 
were found to vary. Activities of these enzymes or their levels in hepatocellular carcinoma 
were always lower than those in initiation and promotion stages (Vessey, 1996). These 
reports suggest that the effects of Phase I hepatic drug metabolism is dwindled in 
hepatocellular carcinoma. The importance of glucose-6-phosphatase (G6P) in preneoplastic 
and neoplastic liver cannot be ruled out. The enzyme catalyzes in the final biochemical 
reactions of both gluconeogenesis and glycogenolysis (Nordlie & Sukalski, 1986; Shieh et al., 
2003). This enzyme has an important role in blood glucose homeostasis (Nordlie & Sukalski, 
1986). Histochemical demonstrations of G6P exhibited less pronounced activity in some 
cancer lesions and enhanced activity in the others. G6P-negative hepatocellular carcinoma 
(Figure 5) was also found to be basophilic (Mukherjee et al., 2007; Hwang et al., 2004). 
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Reports suggest that mutation in the G6P gene, G727T, leads to hepatocellular carcinoma 
(Nordlie & Sukalski, 1986).  
Upon exposure of carcinogens, mutagens or other xenobiotics, reactive oxygen species are 
generated in the cells. Intracellular reactive oxygen species produce different types of DNA  
   
A 
 
B 
Fig. 5. No predominant glucose-6-phosphatase expression in tumor area (A) of a basophilic 
tumor (B). (Mukherjee at al. 2007) 
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damage, including chromosomal aberrations, sister chromatid exchanges, and mutations 
(Dahm, 1996), leading to the initiation and/ or promotion and/ or progression of the 
cancerous process. Oxidative stress resulting from the imbalance of free radicals and the 
cellular antioxidant defense enzyme systems is reported to induce damage to cellular 
membranes and nuclear DNA, which results in lipid peroxidation and oxidative DNA 
damage, respectively (Dahm, 1996). Oxidation of the C8 of guanine which gives rise to the 
formation of modified base 8-hydroxy-2'-deoxyguanosine (8-OHdG) is one of the most 
abundant types of oxidative DNA damage (Kasai & Nishimura, 1986). It is therefore 
considered as a sensitive biomarker for cancer development and an important molecular 
epidemiological assessment of cancer risk due to oxidative stress (Romano et al., 2000). The 
lipid peroxidation, another important chemical reaction owing to the oxidative stress during 
hepatocarcinogenesis, is known to influence tumor growth (Gelderblom,2001). 
6. Signaling of hepatocellular carcinoma: A special reference to the genes, 
Insulin-like-growth factor II (IGF II) and c-raf.1  
Accumulation of mutations in a variety of genes transforms phenotypes of cancer cells. 
Mutations are found in several important genes, including p73, p53, rb, APC, DLC-1(deleted 
in liver cancer), p16, PTEN, IGF-2, BRCA2, SOCS-1, Smad2 and Smad4, ß-catenin, c-myc, 
and cyclinD1, in hepatocellular carcinoma (Farber & Sarma, 1987). These gene products 
normally modulate biochemical pathways that regulate cell death and cell proliferation. 
Deregulation of signaling pathways during the development of hepatocellular carcinoma 
affects normal cellular processes such as cell cycle and apoptosis. Many growth factors such 
as insulin-like growth factor I and II (IGF I/II) have ubiquitous role in the development of 
the disease.  Raf/MEK/ ERK/MAP (Mitogen Activated Protein) kinase pathway, Akt 
pathway, Wnt pathway and Ink4A pathway are some of the predominant pathways 
involved in the neoplastic conversion of normal cells.  However, here our focus is to 
establish the role of IGF II and c-raf.1 in Raf/MEK/ ERK/MAP kinase pathway during the 
development of hepatocellular carcinoma in hepatocarcinogenesis.  
6.1 Insulin-like growth factor II (IGF II) 
Insulin-like growth factor II (IGF II), a mitogenic polypeptide, has been widely implicated in 
the pathogenesis of neoplasm of different tissues including the liver of rats and men (Li et 
al., 1998; Mukherjee et al., 2005). This growth factor is found to express in neonatal life (in 
the first few days after birth) and then during neoplasia in rodents and men (Li et al., 1998; 
Mukherjee et al., 2007). IGF II in signaling for cancer cell proliferation is mediated through 
the Raf growth factor (Das et al., 2010). IGF II activates c-raf through signaling proteins such 
as Grb2 and Ras. Thus, the pathological implication of the overexpression of these two genes 
during the development of hepatocellular carcinoma cannot be ignored. 
The correlation between IGF II expression and cancer development has been reported in a 
number of works (Mukherjee et al., 2005, 2007; Li et al., 1998). In a majority of liver 
carcinoma, IGF-II mRNA expression was reactivated and high levels of IGF-II expression 
were detected. We also investigated to understand the stage(s) at which IGF II gene activates 
during carcinogenesis. In our study, IGF II overexpression was observed in the early hepatic 
altered lesions (Figure 6A, B, C, D) and in hepatocellular carcinoma (Figure 7) (Mukherjee et  
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Fig. 6. A. Hepatic section of an experimental animal showing glycogen-stored early 
preneoplastic focal lesion with Periodic Acid Schiff reaction. (Mukherjee et al. 2007) 
 
 
Fig. 6. B. IGF II mRNA-expressed glycogen storage early preneoplastic lesion detected with 
Digoxigenin-labeled antisense IGF II mRNA by in situ hybridization from the consecutive 
section. pv – portal vein. bd – bile duct. (Mukherjee et al. 2005) 
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Fig. 6. C. Consecutive hepatic section after Digoxigenin-labeled sense IGF II mRNA 
treatment during in situ hybridization method. (Mukherjee et al. 2007) 
 
 
Fig. 6. D. IGF II-expressed one of the early preneoplastic lesions in an animal of initiation 
group. (Mukherjee et al.2005) 
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al., 2005). IGF II gene expressed in the sequence of events leading from glycogen-rich-
acidophilic lesions to glycogen poor basophilic lesions through intermediate type lesions to 
hepatocellular carcinoma with an expression pattern of “high-low-high” in terms of degree 
of expression. More precisely, IGF II overexpression was found to be predominant in 
hepatocellular carcinoma and partially in early preneoplastic lesions. Thus, the gene has an 
essential role at the initiation stage of carcinogenesis (first few weeks) and during 
hepatocellular carcinoma development. 
 
Fig. 7. IGF II mRNA expression in hepatocytes in tumor area (hepatocellular carcinoma) in 
experimental animals. (Mukherjee et al. 2005) 
6.2 The Ras/raf/MEK/ ERK/MAP kinase pathway 
The MAP kinase pathway has probably undergone the most extensive characterization in 
the process of development of hepatocellular carcinoma. Binding of a growth factor to a 
tyrosine kinase receptor causes receptor phosphorylation, leading to the formation of a 
molecular complex with an adaptor protein growth factor receptor bound-2 (Grb2), Grb-2 
associated binder 1 and signal relay protein SH-2 domain-containing tyrosine phosphatase-
2. This is then localized in the plasma membrane. Other protein such as an exchange factor, 
Son-of-sevenless (SOS) joins. This complex activates ras while exchange GDP to GTP in the 
ras/raf/MEK/ERK/MAP kinase pathway. Ras/raf/MEK/ ERK/MAP kinase pathway is 
known to involve in cell proliferation, dedifferentiation, angiogenesis and cell survival 
process (Rapp, 1991). Activation of the components of this pathway has been reported to 
contribute to tumorigenesis, including liver cancer. The GTPase (Guanine neucleotides 
triphosphate)-Ras and the serine/threonine kinase raf (signaling regulators) regulate the 
signaling process immediately by activating raf which then phosphorylates the 
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mitogen/extracellular protein kinase kinases, MEK-1 and MEK-2. MEK proteins then 
phosphorylate the downstream extracellular signal-regulated kinase (ERK) signaling 
molecules, ERK-1 and ERK-2. GTPase-Ras is a switch protein which alternates between an 
active on state with a bound GTP and an inactive off state with a bound GDP (Polakis & 
McCormick, 1992).  Activation of ERK-1 and ERK-2 regulates many target proteins and gene 
regulation proteins in cytoplasm and nucleus.  Ras protein of this pathway is found to 
involve other signaling pathways such as phosphoinositol-3-kinase/Akt pathway, 
Phospholipase C/protein kinase C pathway and Ral guanine nucleotide dissociation 
stimulator pathway. 
The c-raf.1 is a direct downstream effector of ras. The signaling molecule c-raf.1 is one of the 
three highly conserved members (raf A, raf B and c-raf.1) of the raf gene family, which code for 
serine threonine-specific protein kinases in ras-mediated signal transduction pathway (Daum 
et al., 1994; Rapp, 1991; Sebolt-Leopold, 2000). The c-raf.1 has a crucial role in diverse signal 
transduction pathways (Rapp, 1991). The c-raf.1 protein kinase has oncogenic potential and is 
found to be up-regulated in tumors (Störm SM et al. 1993; Stanton VP Jr et al. 1987) and highly 
expressed in hepatocellular carcinoma too (Rapp,1991; Störm et al., 1993). An excessive 
activation of the MAPK pathway was  observed in hepatocellular carcinoma (Rapp,1991). This 
findings and another findings that shows overexpression of c-raf in hepatocellular carcinoma 
in all the 30 different tissue specimens as tested by Hwang et al. (Hwang et al., 2004) thus 
suggest the predominant role of the raf protein as well as ras/raf/MEK/ERK/MAP kinase 
pathway in hepatocellular carcinoma. In a phase-wise study (initiation/ promotion/ 
hepatocellular carcinoma) in rat hepatocarcinogenesis model (Mukherjee et al., 2007), we  
 
Fig. 8. A predominant raf-expressed late basophilic lesion (shown by arrows) in animal of 
cancer control group. (Das et al. 2009) 
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wanted to investigate the stage(s) at which c-raf.1 overexpression occurs. Our findings (as 
studied by in-situ hybridization) suggest that overexpression of the gene (Figure 8) occurs at 
the late stage basophilic focal lesions and in hepatocellular carcinoma. Further, c-raf.1 
mediated activation of ras/raf/MEK/ERK/MAP kinase pathway may be a late stage 
phenomenon during the development of hepatocellular carcinoma and the activation may 
be either through c-raf.1 oncogenic mutation or by constitutive c-raf.1 activation by other 
deregulated proteins such as growth factors during hepatocarcinogenesis. Thus, constitutive 
activation of this pathway at one or more steps, particularly at ras or raf, can lead to a 
malignant state. However, no predominant difference is noticed between constitutive 
activation of Raf and Ras (Zang et al., 2002). 
7. Conclusion 
Unlike IGF II, c-raf.1 overexpression was observed in the late basophilic lesions associated 
with hepatocellular carcinoma. Thus, IGF II may have a role in activation of c-raf.1 signaling 
in the late stage of development of cancer. The role of raf.1 protein in IGF-induced signaling 
has been reported (Evert et al., 2004). But, when does it happen during the process of 
development of hepatocellular carcinoma? The c-raf.1 gene overexpression was 
predominantly found in hepatocellular carcinoma and late basophilic foci. Thus, the 
overexpression of c-raf.1 has been considered as a late-stage phenomenon during 
hepatocarcinogenesis (Bannasch, 2010). However, overexpression of c-raf.1 in very early 
lesion was also reported (He & Gascon- Barre, 1997). In our study, the dissection of 
animals after 7-8 weeks of carcinogenic insult did not show any raf.1-expressed lesions. 
Further, it was reported that c-raf.1 expressed in the basophilic tumors (Hwang et al., 
2004). IGF II gene overexpression was noticed in the preneoplastic lesions and in 
hepatocellular carcinoma. On the other hand, overexpression of c-raf.1 gene was seen in 
the basophilic lesions associated with hepatocellular carcinoma as well as in tumor. While 
correlating the expression patterns of IGF II and c-raf.1, it suggests that IGF II-induced 
cellular signaling may be mediated through and/or affected by c-raf.1 in hepatocellular 
carcinoma and in the late stage of development of cancer. Thus, IGF II mediated c-raf.1 
activation may drive late preneoplastic lesions towards neoplasia. 
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